Medicine and Dentistry
Systematic Review
100%
Biological Product
100%
Rheumatoid Arthritis
100%
Methotrexate
100%
Network Meta-Analysis
100%
Tocilizumab
100%
Inflammatory Arthritis
100%
Randomized Controlled Trial
33%
Rheumatic Disease
33%
Diseases
33%
Placebo
16%
Interleukin 6
16%
Receptor
16%
Monotherapy
16%
Infliximab
16%
Adalimumab
16%
Certolizumab Pegol
16%
Rituximab
16%
Etanercept
16%
Abatacept
16%
Golimumab
16%
Nursing and Health Professions
Systematic Review
100%
Biological Product
100%
Rheumatoid Arthritis
100%
Methotrexate
100%
Tocilizumab
100%
Network Meta-Analysis
100%
Inflammatory Arthritis
100%
Rheumatic Disease
33%
Diseases
33%
Monotherapy
16%
Placebo
16%
Infliximab
16%
Interleukin 6
16%
Receptor
16%
Adalimumab
16%
Etanercept
16%
Certolizumab Pegol
16%
Golimumab
16%
Rituximab
16%
Abatacept
16%
Keyphrases
Rheumatoid Arthritis
100%
Comparative Effectiveness
100%
Network Meta-analysis
100%
Tocilizumab
100%
ACR50
66%
European League against Rheumatism (EULAR)
50%
ACR20
50%
Randomized Controlled Trial
33%
Rheumatologic Diseases
33%
Disease-modifying Agents
33%
Placebo
16%
Monotherapy
16%
Treatment Failure
16%
Mechanism of Action
16%
Abatacept
16%
Rituximab
16%
Adalimumab
16%
Golimumab
16%
Methotrexate
16%
Certolizumab Pegol
16%
Etanercept
16%
Infliximab
16%
Anti-IL-6 Receptor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
100%
Biological Product
100%
Methotrexate
100%
Tocilizumab
100%
Inflammatory Arthritis
100%
Randomized Controlled Trial
33%
Rheumatic Disease
33%
Diseases
33%
Interleukin 6
16%
Placebo
16%
Receptor
16%
Monotherapy
16%
Infliximab
16%
Adalimumab
16%
Etanercept
16%
Golimumab
16%
Certolizumab Pegol
16%
Rituximab
16%
Abatacept
16%
Immunology and Microbiology
Biological Product
100%
Inflammatory Arthritis
100%
Methotrexate
100%
Tocilizumab
100%
Rheumatic Disease
33%
Interleukin 6
16%
Adalimumab
16%
Infliximab
16%
Rituximab
16%
Golimumab
16%
Certolizumab Pegol
16%
Etanercept
16%
Abatacept
16%
INIS
reviews
100%
arthritis
100%
management
100%
diseases
50%
comparative evaluations
50%
rheumatoid diseases
50%
receptors
25%
adults
25%
methotrexate
25%
Agricultural and Biological Sciences
Meta-Analysis
100%
Systematic Review
100%
Placebo
20%
Receptor
20%
Infliximab
20%
Rituximab
20%
Adalimumab
20%
Interleukin 6
20%